ProMIS Set to Transform Alzheimer's Treatment Landscape with PMN310
AI Prediction of ProMIS Neurosciences Inc. Common Shares (ON) (PMN)
ProMIS Neurosciences, focusing on antibody therapeutics for neurodegenerative diseases, is nearing significant clinical milestones for its lead candidate PMN310 in Alzheimer's disease. Upcoming data from the PRECISE-AD trial could drive substantial value.
ProMIS Neurosciences is a biotech firm dedicated to developing selective antibody treatments for neurodegenerative diseases, with a primary focus on Alzheimer's disease through their lead candidate, PMN310. The company's proprietary EpiSelect platform identifies specific epitopes on misfolded proteins, allowing for targeted therapy development. PMN310 is currently undergoing a Phase 1b trial (PRECISE-AD), with interim data expected in Q3 2026. Positive results could validate PMN310's efficacy and safety, potentially setting it apart from existing treatments by minimizing risks associated with amyloid-related imaging abnormalities (ARIA). The upcoming trial outcomes are critical, given the high unmet medical need and the large market for Alzheimer's therapies.
PMN Report Information
Prediction Date2026-04-02
Close @ Prediction$13.00
Mkt Cap117m
IPO Date2005-09-30
AI-derived Information
Recent News for PMN
- Mar 25, 8:00 am — ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire)
- Mar 18, 8:00 am — ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD) (GlobeNewswire)
- Feb 9, 8:35 am — Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack (24/7 Wall St.)
- Feb 4, 4:05 pm — ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
- Jan 30, 8:00 am — ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing (GlobeNewswire)
- Dec 18, 7:30 am — ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease (GlobeNewswire)
- Dec 10, 7:30 am — ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk (GlobeNewswire)
- Dec 1, 7:30 am — ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 (GlobeNewswire)
- Dec 1, 7:00 am — ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
- Nov 24, 8:00 am — ProMIS Neurosciences Announces Reverse Stock Split (GlobeNewswire)
- Nov 12, 7:00 am — ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire)
- Nov 3, 4:05 pm — ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
NDAPR (News-Driven AI Prediction Revision) events for PMN
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest